News stories about Eli Lilly and (NYSE:LLY) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eli Lilly and earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.086664725781 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
LLY has been the topic of a number of recent research reports. Credit Suisse Group lowered shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their price objective for the company from $84.23 to $88.00 in a research note on Tuesday, October 10th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a research note on Thursday, October 26th. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Wednesday, November 1st. Morgan Stanley lifted their price objective on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 21st. Finally, Cowen restated a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a research note on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Hold” and an average target price of $92.14.
Shares of Eli Lilly and (LLY) traded up $1.05 during trading on Friday, hitting $86.57. 2,910,172 shares of the stock were exchanged, compared to its average volume of 2,966,596. Eli Lilly and has a twelve month low of $74.00 and a twelve month high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $95,321.79, a price-to-earnings ratio of 41.03, a price-to-earnings-growth ratio of 1.62 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same period in the previous year, the business posted $0.88 earnings per share. The business’s revenue was up 9.0% compared to the same quarter last year. equities analysts forecast that Eli Lilly and will post 4.22 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.60%. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is presently 98.58%.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the transaction, the insider now owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Insiders have sold 251,088 shares of company stock worth $22,041,236 over the last 90 days. 0.20% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/07/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-eli-lilly-and-lly-share-price.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.